Please login to the form below

Not currently logged in
Email:
Password:

Ablynx reshuffles its board again

Dr Bo Jesper Hansen resigns from the Belgium biotech's board

Dr Bo Jesper HansenAfter one month as Ablynx’s chairman of the board of directors, Dr Bo Jesper Hansen (pictured) has resigned from the position due to personal reasons.

Dr Hansen will be succeeded by Dr Russell Greig, who will also become a permanent representative of Greig Biotechnology Global Consulting.

Dr Greig has been non-executive director of Ablynx since 2012, and has been unanimously elected by the board to be the biotech’s new chairman.

To date he has served in various roles during his 28-year career at GlaxoSmithKline, where he most recently served as president for both GSK Pharmaceuticals and SROne, the venture arm of GSK.

Dr Edwin Moses, chief executive officer of Ablynx, said: “We are very fortunate to have a very suitable successor for Bo Jesper, allowing for an orderly transition at this time.

“Russell knows the company extremely well and will be an important asset during the next months.”

14th February 2018

From: Sales

Share

Tags

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
Dovetail

We’re a specialist health consultancy that supports companies, healthcare professionals and patients to work hand in hand with a common...

Latest intelligence

Mainimage2
The role of digital health technology tools in supporting medical adherence
How DHT-based digital interventions can help to support patients and improve adherence...
How To Tell A Better Silent Story
They say a picture's worth 1,000 words, which is incredibly helpful when telling a silent story....
Main image1
Global leaders in digital channels
Exploring why UK field teams are global leaders in digital channels is key to better understanding the changes in omnichannel engagement...